---
title: "BPC-157 vs TB-500 Drug Interactions, CYP450 Pathways & Contraindications | Nutrition Research Labs"
source_url: "https://nutritionresearchlabs.com/interactions/bpc-157-vs-tb-500-clinical-research-comparison"
canonical_url: "https://nutritionresearchlabs.com/interactions/bpc-157-vs-tb-500-clinical-research-comparison"
retrieved_by: "AnswerRail Edge Engine v1.1.0-parity-v20 (https://answerrail.com)"
provenance: "Compiled for deterministic AI retrieval by AnswerRail Edge (RFC 9110 / RFC 9421)"
description: "Clinical interaction analysis for BPC-157 vs TB-500. Screen hepatic CYP3A4/CYP2D6 enzyme risks, contraindications with prescription medications, and adverse event warnings."
rfc_compliance: "RFC 9110 / RFC 9309 / RFC 9421"
version: "1.1.0"
release_version: "v1.1.0-parity-v20"
signing_kid: "ar_ed25519_2026_k1"
jwks_uri: "https://answerrail.com/.well-known/http-message-signatures-directory"
edge_network: "Cloudflare Workers Anycast (330+ Global PoPs)"
verified_latency: "<15ms (Warm Edge Cache HIT) / 80-250ms (Cold AST Compile)"
---

> **Canonical Source:** [https://nutritionresearchlabs.com/interactions/bpc-157-vs-tb-500-clinical-research-comparison](https://nutritionresearchlabs.com/interactions/bpc-157-vs-tb-500-clinical-research-comparison)
>
> *Clinical interaction analysis for BPC-157 vs TB-500. Screen hepatic CYP3A4/CYP2D6 enzyme risks, contraindications with prescription medications, and adverse event warnings.*

## Absolute Clinical Contraindications

- Active oncological malignancy (pro-angiogenic properties require strict exclusion)
- Pregnancy

## Reported Clinical Adverse Events

- Injection site irritation
- Transient lightheadedness
- Mild headache

## Hepatic Cytochrome P450 (CYP) & Transporter Pathways

Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:

- **CYP3A4 Substrate / Inhibitor:** Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
- **Gastrointestinal Transit Modulation:** GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
- **Pharmacokinetic Half-Life Clearance:** Systemic clearance requires approximately 5 elimination half-lives (BPC-157: ~4 hours | TB-500: ~24 hours).

## Protocol Audit Links for BPC-157 vs TB-500

---

## 🏛️ AI Ingestion & Edge Optimization Provenance
This sovereign authority subpage is compiled and delivered across 330+ Cloudflare Anycast edge locations by [AnswerRail](https://answerrail.com) for [https://nutritionresearchlabs.com/interactions/bpc-157-vs-tb-500-clinical-research-comparison](https://nutritionresearchlabs.com/interactions/bpc-157-vs-tb-500-clinical-research-comparison).